Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 4.6% – Should You Sell?

Shares of Ascendis Pharma A/S (NASDAQ:ASND) were down 4.6% during trading on Wednesday . The stock traded as low as $128.41 and last traded at $125.07. Approximately 13,803 shares were traded during mid-day trading, a decline of 97% from the average daily volume of 420,233 shares. The stock had previously closed at $131.06.

Analyst Ratings Changes

ASND has been the subject of several research reports. Wedbush reissued an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. UBS Group initiated coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 price objective on the stock. Oppenheimer dropped their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. JPMorgan Chase & Co. cut their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus target price of $192.07.

Ascendis Pharma A/S Trading Up 0.6 %

The company has a 50-day moving average of $133.25 and a 200-day moving average of $133.30. The company has a market capitalization of $7.78 billion, a price-to-earnings ratio of -15.87 and a beta of 0.65.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its holdings in Ascendis Pharma A/S by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares during the period. Profund Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 3.0% in the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after acquiring an additional 85 shares during the period. Marshall Wace LLP raised its holdings in shares of Ascendis Pharma A/S by 20.8% during the second quarter. Marshall Wace LLP now owns 30,289 shares of the biotechnology company’s stock worth $4,131,000 after purchasing an additional 5,205 shares during the last quarter. Lighthouse Investment Partners LLC acquired a new position in Ascendis Pharma A/S during the second quarter valued at $2,762,000. Finally, Algert Global LLC boosted its holdings in Ascendis Pharma A/S by 54.6% in the second quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 770 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.